Royalty Pharma PLC reports results for the quarter ended in June - Earnings Summary

Royalty Pharma

08/08/2024 19:58

* Royalty Pharma PLC  RPRX.OQ  reported quarterly adjusted
earnings of 96 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of 84 cents.  The mean expectation of six analysts
for the quarter was for earnings of 97 cents per share. Wall
Street expected results to range from 92 cents to $1.07 per
share.
    * Revenue rose 13% to $608.00 million from a year ago;
analysts
expected $628.53 million. 
    * Royalty Pharma PLC's reported EPS for the quarter was 23
cents​.
    * The company reported quarterly net income of $102 million.
    * Royalty Pharma PLC shares had risen by 3.3% this
quarter and
lost 3.0% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 1.7%
in the last three months.​ 
    * In the last 30 days, one analyst negatively revised an
earnings
estimate

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the
pharmaceuticals
peer group is also "buy"

Wall Street's median 12-month price target for Royalty Pharma
PLC is $46.00 
This summary was machine generated from LSEG data August 8 at
06:58 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      0.97           0.96           Missed
 Mar. 31 2024      0.98           0.98           Met
 Dec. 31 2023      1.01           1.15           Beat
 Sep. 30 2023      0.76           0.79           Beat